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tional ability to invadenerves throughpronounced crosstalk be-
tween nerves and cancer cells; however, the mechanism of
PDAC cell invasion remains to be elucidated. Here, we demon-
strate the therapeutic potential of telomerase-specific oncolytic
adenoviruses, OBP-301 and tumor suppressor p53-armed
OBP-702, against human PDAC cells. Highly invasive PDAC
cells exhibited higher levels of phosphorylated extracellular
signal-regulated kinases 1 and 2 (ERK1/2) expression indepen-
dent of KRAS expression; ERK1/2 inhibitor or small interfering
RNA (siRNA) treatment significantly reduced the migration
and invasion of PDAC cells, suggesting that the ERK signaling
pathway is associatedwith the invasiveness of PDAC cells. OBP-
702 infection suppressed ERK signaling and inhibited PDAC
cell migration and invasion more efficiently than OBP-301.
OBP-702 also effectively inhibited PDAC cell invasion even
when invasiveness was enhanced by administration of motility
stimulators, such as nerve and neurosecretory factors. More-
over, noninvasive whole-body imaging analyses showed that
OBP-702 significantly suppressed tumor growth in an ortho-
topic PDAC xenograft model, although both viruses were
equally effective against subcutaneous tumors, suggesting that
OBP-702 can influence the orthotopic tumor microenviron-
ment. Our data suggest that oncolytic virus-mediated disrup-
tion of ERK signaling is a promising antitumor strategy for
attenuating the invasiveness of PDAC cells.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal type of
cancer. The disease has a poor prognosis, with a 5-year survival rate
of only 8%, despite recent advances in the treatment of PDAC.1 The
poor prognosis of PDAC is primarily due to early onset of local recur-
rence and distant metastasis. Perineural invasion (PNI) is one of the
main causes of recurrence and metastasis after curative surgery.2,3
The presence of cancer cells within the epineurial, perineurial, or endo-Molecula
This is an open access article under the CC BY-NC-neurial spaces of the neural sheath, as defined by Liebig et al.,4 occurs in
PDAC at a higher incidence (80%–100%) than any other type of can-
cer.2 The underlying mechanism of PNI reportedly involves mutual
neurotrophic crosstalk between PDAC cells and surrounding nerves.5
Nerves in the tumormicroenvironment stimulate the growth and inva-
sion of PDAC cells via the secretion of neurotransmitters (catechol-
amines and acetylcholine) and neurotrophic growth factors (nerve
growth factor [NGF] and glial cell line-derived neurotrophic factor
[GDNF]).6 Althoughnerve infiltration in the tumormicroenvironment
plays a crucial role in the progression of PDAC, there is currently no
attractive strategy for limiting the invasiveness of PDAC cells.
The primary treatment option for locally advanced or metastatic
PDAC is chemotherapy.7 Gemcitabine has been used as the standard
first-line treatment; however, the 1-year survival rate of PDAC patients
after treatment with gemcitabine is only 17%–23%.8 Recently, interest
in the chemotherapeutic use of FOLFILINOX,9 nab-paclitaxel,10 and
the molecular-targeted agent erlotinib11 has grown; however, these
therapies do not markedly improve the clinical outcome of PDAC pa-
tients. Oncolytic virotherapy recently emerged as a novel antitumor
therapy against PDAC.12–14 The telomerase-specific virus OBP-301
(telomelysin), in which the human telomerase reverse transcriptase
(hTERT) promoter drives expression of the E1A and E1B genes for tu-
mor-specific virus replication, exhibits broad-spectrum antitumor ef-
fects against many types of cancer, including PDAC.15–17 We also
generated a modified OBP-301 variant (OBP-702) that induces the tu-
mor suppressor gene p53 by inserting the Egr1 promoter-driven p53
expression cassette into the E3 region of OBP-301.18 OBP-702 ex-
hibited greater antitumor efficacy than OBP-301 through activationr Therapy: Oncolytics Vol. 17 June 2020 ª 2020 The Author(s). 107
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Induction of Autophagy- and Apoptosis-Related Death of Human Pancreatic Ductal Adenocarcinoma (PDAC) Cells Infected with OBP-301 or
OBP-702
(A) The cytopathic effect of OBP-301 and OBP-702 against four PDAC cell lines (Capan-1, MIA PaCa-2, BxPC-3, Panc-1). Cell viability was determined 72 h after infection
with OBP-301 or OBP-702 at the indicated MOI using an XTT assay. Cell viability was calculated relative to that of mock-infected cells, the viability of which was set at 1.0.
Data are expressed as mean ± SD (n = 5). *p < 0.05 (versus 0 MOI). (B and C) Expression of the apoptosis markers PARP and cleaved PARP (C-PARP), autophagy marker
p62, viral EIA, and p53 proteins in PDAC cells infected with OBP-301 or OBP-702 at the indicated MOI for 72 h. b-Actin was assayed as a loading control.
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targeted tumor cells,18–20 suggesting that OBP-702 has therapeutic po-
tential against various p53-inactivated cancers, including PDAC.21
In the present study, we hypothesized that the mitogen-activated pro-
tein kinase (MAPK) signaling pathway is associated with invasiveness
of PDAC cells. We evaluated the therapeutic potential of the telome-
rase-specific oncolytic adenovirus OBP-301 and p53-activating virus
OBP-702 against the malignant behavior of PDAC cells. Moreover,
in vivo preclinical experiments using an orthotopic PDAC xenograft
tumor model were performed to assess the virus-mediated antitumor
activity.
RESULTS
In Vitro Cytopathic Effect of OBP-301 and OBP-702 against p53
Mutant PDAC Cells
To determine the therapeutic potential of telomerase-specific oncolytic
adenoviruses for treating PDAC, we investigated the in vitro cytopathic
effect of OBP-301 and OBP-702 against four human PDAC cell lines
(Capan-1,MIAPaCa-2, BxPC-3, andPanc-1)with p53mutations using108 Molecular Therapy: Oncolytics Vol. 17 June 2020an sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-me-
thoxy6-nitro) benzene sulfonic acid hydrate (XTT) assay of cell viability
on day 3 after viral infection. Infection with OBP-301 at high doses
(multiplicity of infection [MOI] of 50 and 100) significantly suppressed
cell viability, whereas infection with OBP-702 at either low (MOI of 5
and 10) or high (MOI of 50 and 100) doses significantly suppressed
the viability of all human PDAC cell lines examined (Figure 1A),
demonstrating more profound antitumor efficacy of OBP-702 than
OBP-301 for treating PDAC. OBP-702 is generated by inserting the
p53 expression cassette into the E3 region of OBP-301.18 To rule out
the possibility that E3modification induces the profound antitumor ef-
fect ofOBP-702,we analyzed the cytopathic effect ofOBP-401, inwhich
the non-toxic green fluorescent protein (GFP) expression cassette is in-
serted into the E3 region of OBP-301.22 The cytopathic effect of GFP-
expressing OBP-401 was almost similar with that of OBP-301 in
Capan-1, BxPC-3, and Panc-1 cells, althoughMIA PaCa-2 cells slightly
showed higher sensitivity toOBP-401 thanOBP-301 (Figure S1). These
results suggest that OBP-702 induces more profound antitumor effect
thanOBP-301 in PDAC cells, probably because of p53 activation rather
than E3 modification.
Figure 2. Characterization of the Migration and Invasion Properties of PDAC Cells
(A) The number of migrating or invading cells in five randomly selected fields was determined under a light microscope. Representative photomicrographs of migrating and
invading cells stained with crystal violet. Original magnification 100. Data are expressed as mean ± SD (n = 5). (B) Expression of KRAS, phospho-ERK1/2 (p-ERK1/2), and
ERK1/2 proteins in PDAC cells. b-Actin was assayed as a loading control.
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Capan-1 and MIA PaCa-2 cells (Figure 1A). To explore the mecha-
nism of high sensitivity to OBP-702 in PDAC cells, we analyzed the
expression level of coxsackie and adenovirus receptor (CAR) in
four human PDAC cell lines by flow cytometry. BxPC-3 and Panc-
1 cells showed higher CAR expression than Capan-1 and MIA
PaCa-2 cells (Figure S2). These results suggest that BxPC-3 and
Panc-1 cells are sensitive to OBP-702 due to high CAR expression.
To explore the mechanism of the oncolytic adenovirus-induced cyto-
pathic effect against PDAC cells, we conducted western blot analyses
of apoptosis and autophagy (Figures 1B and 1C). OBP-301 infection
at a high dose resulted in a slight increase in the expression of the
apoptosis-specific marker cleaved poly(ADP-ribose) polymerase
(C-PARP) in Capan-1, MIA PaCa-2, and BxPC-3 cells, but not in
Panc-1 cells. Decreased expression of the autophagy-specific marker
p62 was observed in all PDAC cells treated with OBP-301 at high
doses, suggesting that OBP-301 primarily induces autophagy rather
than apoptosis. By contrast, OBP-702 infection at low and high doses
resulted in increased C-PARP expression and decreased p62 expres-
sion (Figure 1C), suggesting that both apoptosis and autophagy are
involved in the OBP-702-induced antitumor effect. Moreover, p53
expression increased in cells treated with OBP-702 but decreased incells treated with OBP-301, although both OBP-301 and OBP-702
effectively induced adenoviral E1A expression. These results indicate
that the telomerase-specific oncolytic adenoviruses OBP-301 and
OBP-702 exhibit cytopathic effects that involve autophagy and
apoptosis in p53 mutant PDAC cells.
Invasive Phenotype of PDAC Cells Is Associated with Activation
of the MAPK Signaling Pathway
Next, we sought to characterize the migration and invasion of PDAC
cells using Boyden chamber-based assays. Both Capan-1 and MIA
PaCa-2 cells exhibited low migration and invasion capabilities,
whereas BxPC-3 and Panc-1 cells exhibited a high capacity to migrate
and invade (Figure 2A), suggesting that BxPC-3 and Panc-1 cells
migrate and invade tissues more aggressively than Capan-1 and
MIA PaCa-2 cells. By contrast, analyses of cell proliferation showed
that MIA PaCa-2 and Panc-1 cells proliferate more rapidly than Ca-
pan-1 and BxPC-3 cells (Figure S1). These results suggest that
although BxPC-3 and Panc-1 cells exhibit an invasive phenotype, it
is not correlated with rapid cell proliferation.
Because constitutive activation of the KRAS-MAPK signaling
pathway is associated with the malignant phenotype of PDAC
cells,23,24 we evaluated the expression of KRAS and extracellularMolecular Therapy: Oncolytics Vol. 17 June 2020 109
Figure 3. OBP-301 and OBP-702 Inhibit the Migration and Invasion of Highly Invasive PDAC Cells by Suppressing KRAS-ERK Signaling
(A) Migration and invasion assay using highly invasive PDAC cells infected with OBP-301 or OBP-702 at the indicated MOI for 24 h. *p < 0.05 (versus 0MOI). (B) Expression of
KRAS, phospho-ERK1/2 (p-ERK1/2), and ERK1/2 proteins in highly invasive PDAC cells infected with OBP-301 or OBP-702 at the indicated MOI for 24 h. (C) Migration and
invasion assay and western blot analysis of KRAS expression in highly invasive PDAC cells transfected with 10 nM KRAS siRNA (si-KRAS) for 72 h. (D) Migration and invasion
assay and western blot analysis of p-ERK1/2 and ERK1/2 expression in highly invasive PDAC cells transfected with 10 nM ERK1/2 siRNA (si-ERK1/2) for 72 h. Control siRNA
(si-con) was used as a control. b-Actin was assayed as a loading control. The number of migrating and invading cells after treatment was calculated relative to that of non-
treated cells, which was set at 1.0. Data are expressed as mean ± SD (n = 5). *p < 0.05 (versus si-con).
Molecular Therapy: Oncolyticssignal-regulated kinase (ERK) proteins. Capan-1, MIA PaCa-2, and
Panc-1 cells are KRAS mutant type, and BxPC-3 cells are KRAS
wild type. Western blot analyses demonstrated that high and mod-
erate KRAS expression were observed in highly invasive Panc-1 and
BxPC-3 cells and poorly invasive Capan-1 cells, whereas poorly
invasive MIA PaCa-2 cells exhibited low KRAS expression, suggest-
ing no relationship between invasive phenotype and KRAS expres-
sion. In contrast, the expression of phosphorylated ERK1/2 was high
in highly invasive BxPC-3 and Panc-1 cells, but not in poorly inva-
sive Capan-1 and MIA PaCa-2 cells (Figure 2B). These results sug-
gest that activation of the ERK signaling pathway is associated with
the migration and invasion capabilities of PDAC cells independent
of KRAS status.110 Molecular Therapy: Oncolytics Vol. 17 June 2020Oncolytic Viruses Inhibit the Migration and Invasion of PDAC
Cells by Suppressing the KRAS-MAPK Signaling Pathway
The therapeutic potential of oncolytic adenoviruses for inhibiting
PDAC cell migration and invasion was analyzed using highly inva-
sive BxPC-3 and Panc-1 cells. Although infection with OBP-301
and OBP-702 for 24 h did not decrease the viability of either
BxPC-3 or Panc-1 cells (Figure S4A), the migration and invasion
capabilities of BxPC-3 and Panc-1 cells were significantly sup-
pressed by infection with OBP-301 and OBP-702 for 24 h in a
dose-dependent manner. Although the effect of OBP-702 was
much stronger than that of OBP-301 in BxPC-3 cells, the viruses
exhibited similar effects against Panc-1 cells (Figures 3A and
S4B). These results suggest that both OBP-301 and OBP-702
www.moleculartherapy.orgsuppress the migration and invasion capabilities of PDAC cells
without affecting their cell viabilities.
To explore the mechanism of oncolytic adenovirus-mediated sup-
pression of the invasive phenotype of PDAC cells, we conducted west-
ern blot analyses of KRAS and ERK protein expression. OBP-301 and
OBP-702 induced a similar dose-dependent decrease in the expres-
sion of KRAS protein in BxPC-3 and Panc-1 cells (Figure 3B). By
contrast, the expression of phosphorylated ERK1/2 decreased in
OBP-702-infected PDAC cells, but not OBP-301-infected cells (Fig-
ure 3B). These results suggest that OBP-702 suppresses ERK expres-
sion more efficiently than OBP-301.
To clarify the role of KRAS-MAPK signaling in the invasive pheno-
type of PDAC cells, we conducted migration and invasion assays us-
ing KRAS siRNA and ERK1/2 siRNA. Treatment with KRAS siRNA
or ERK1/2 siRNA significantly suppressed the migration and inva-
sion capabilities of BxPC-3 and Panc-1 cells compared with control
siRNA treatment (Figures 3C and 3D). Interestingly, the effect of
ERK1/2 siRNA was much stronger than that of KRAS siRNA in
BxPC-3 cells, but the effects of both siRNAs were similar in Panc-1
cells. Moreover, treatment with the ERK1/2 inhibitor SCH772984
had a similar effect as treatment with ERK1/2 siRNA in BxPC-3
and Panc-1 cells (Figure S3). These results suggest that suppression
of ERK signaling plays a critical role in OBP-702-mediated suppres-
sion of the invasive phenotype of PDAC cells.
Oncolytic Viruses Suppress the Migration and Invasion
Capabilities of PDAC Cells via Stimulation with Dorsal Root
Ganglion and Neurosecretory Factors
In the pancreatic microenvironment, nerves play a crucial role in
mediating the invasive phenotype of PDAC cells.6 The role of nerves
in enhancing the invasive phenotype of PDAC cells was investigated
using dorsal root ganglia (DRGs) obtained from athymic nude mice.
Neurite outgrowth was confirmed in DRGs cultured in a Matrigel-
coated dish for 7 days (Figure S4A), indicating that harvested DRGs
are suitable for use as nerve tissues. Indeed, the addition of DRGs
significantly increased the migration and invasion capabilities of
BxPC-3 and Panc-1 cells (Figure S4B). To investigate the therapeu-
tic potential of oncolytic adenoviruses in suppressing the nerve-
stimulated invasive phenotype of PDAC cells, we conducted migra-
tion and invasion assays using highly invasive BxPC-3 and Panc-1
cells co-cultured with DRGs. Both OBP-301 and OBP-702 signifi-
cantly suppressed the migration and invasion capabilities of
BxPC-3 and Panc-1 cells in the presence of DRGs (Figure S4C).
These results suggest that OBP-301 and OBP-702 suppress the
nerve-stimulated invasive potential of PDAC cells.
Several neurosecretory factors are involved in the nerve-stimulated
invasion of PDAC cells.6 To evaluate which neurosecretory factors
enhance the invasive phenotype of PDAC cells similar to DRGs, we
examined three neurosecretory factors: norepinephrine (NE), NGF,
and GDNF. Administration of NE significantly increased the migra-
tion capability of BxPC-3 cells, whereas administration of NGF andGDNF significantly enhanced the migration capability of Panc-1 cells
(Figures 4A and S5A). Western blot analyses demonstrated that all
three neurosecretory factors increased the expression of phosphory-
lated ERK in BxPC-3 and Panc-1 cells (Figure 4B).
To investigate the therapeutic potential of oncolytic adenoviruses
for suppressing the neurosecretory factor-enhanced invasive
phenotype of PDAC cells, we conducted migration and invasion
assays using highly invasive BxPC-3 and Panc-1 cells co-cultured
with neurosecretory factors. OBP-301 and OBP-702 significantly
suppressed the migration and invasion capabilities of BxPC-3
and Panc-1 cells in the presence of the neurosecretory factors (Fig-
ure 4C). Although the effect of OBP-702 was much stronger than
that of OBP-301 in BxPC-3 cells, the viruses exhibited similar ef-
fects against Panc-1 cells. Moreover, similar to OBP-301 and
OBP-702, the ERK1/2 inhibitor SCH772984 significantly sup-
pressed the migration and invasion capabilities of BxPC-3 and
Panc-1 cells after stimulation with the neurosecretory factors (Fig-
ure S5C). These results suggest that both OBP-301 and OBP-702
suppress the invasive potential of PDAC cells stimulated with
abundant neurosecretory factors.
Oncolytic Viruses Suppress Tumor Growth in a Subcutaneous
BxPC-3 Xenograft Tumor Model
To evaluate the antitumor effect of oncolytic adenoviruses in
PDAC tumors, we used a subcutaneous BxPC-3 xenograft tumor
model. Intratumoral injection of OBP-301 and OBP-702 signifi-
cantly suppressed tumor growth compared with mock treatment,
whereas there was no significant difference in the volumes of
OBP-301- and OBP-702-treated tumors (Figures 5A–5C). Histo-
pathologic analyses of tumor tissues on day 37 revealed large
necrotic areas in OBP-702-treated tumors, as compared with
OBP-301- or mock-treated tumors (Figure 5D). Immunohistologic
analysis of expression of the cell proliferation marker Ki-67 re-
vealed a significantly lower percentage of Ki-67-positive cancer
cells in OBP-702-treated tumors compared with OBP-301- or
mock-treated tumors (Figures 5D and 5E). These results suggest
that both OBP-301 and OBP-702 suppress the growth of PDAC
tumors, and OBP-702 inhibits the proliferation of PDAC cells in
tumors more strongly than OBP-301.
OBP-702 Suppresses Tumor Growth in an Orthotopic
BxPC-3-Luc Xenograft Tumor Model
To assess the therapeutic efficacy of OBP-301 and OBP-702 against
PDAC tumors within the pancreatic microenvironment, we used an
orthotopic BxPC-3-Luc (luciferase) xenograft tumor model, in which
Luc activity is associated with the viability of PDAC cells in tumors.
Analyses using a noninvasive in vivo imaging system (IVIS) demon-
strated that OBP-702 significantly suppressed the viability of PDAC
cells in tumors, whereas OBP-301 did not suppress the viability of
PDAC cells in tumors when compared with mock treatment (Figures
6A and 6B). These results suggest that OBP-702 has more potential to
suppress the viability of PDAC cells within the pancreatic tumor
microenvironment than OBP-301.Molecular Therapy: Oncolytics Vol. 17 June 2020 111
Figure 4. OBP-301 and OBP-702 Inhibit the Migration and Invasion of Highly Invasive PDAC Cells Stimulated with Neurosecretory Factors
(A) Migration assay using highly invasive PDAC cells stimulated with norepinephrine (NE), nerve growth factor (NGF), or glial cell line-derived neurotrophic factor (GDNF) at the
indicated doses. *p < 0.05 (versus control). (B) Expression of phospho-ERK1/2 (p-ERK1/2) and ERK1/2 proteins in highly invasive PDAC cells stimulated with NE (100 mM),
NGF (100 ng/mL), or GDNF (100 ng/mL) for 24 h. b-Actin was assayed as a loading control. (C) Migration and invasion assay using highly invasive PDAC cells stimulated with
NE (100 mM), NGF (100 ng/mL), or GDNF (100 ng/mL) for 24 h in the presence of OBP-301 (100MOI) or OBP-702 (100MOI). The number of migrating and invading cells after
treatment was calculated relative to that of non-treated cells, which was set at 1.0. Data are expressed as mean ± SD (n = 5). *p < 0.05 (versus NE, NGF, or GDNF).
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The prognosis of patients with PDAC is poor due to the high invasive-
ness, local recurrence, and distant metastasis characteristics of this
disease.2 PNI, one of the most common hallmarks of PDAC, is asso-
ciated with disease recurrence and pain. Therefore, therapies that
target the invasiveness of PDAC cells are needed in order to improve
the clinical outcome of these patients. In this study, we demonstrated
that the telomerase-specific oncolytic adenoviruses OBP-301 and
OBP-702 suppress the growth and invasion of PDAC cells indepen-
dent of KRAS status via the induction of autophagy and apoptosis
and suppression of ERK signaling. Moreover, the p53-activating
OBP-702-mediated antitumor effect was stronger than the p53-non-
expressing OBP-301-mediated effect against PDAC tumors within
the pancreatic tumor microenvironment, which includes nerve tis-
sues and abundant neurosecretory factors. Thus, a p53-armed onco-112 Molecular Therapy: Oncolytics Vol. 17 June 2020lytic virotherapy would be a promising strategy for inhibiting the
growth and invasion of PDAC cells via p53 activation and suppres-
sion of ERK signaling.
The p53 tumor suppressor gene is one of the most frequently mutated
genes in PDAC cells,25,26 which suggests that gene therapy targeting
p53 would be effective against p53-inactivated PDAC.20 However,
whether p53 restoration plays a crucial role in the growth and inva-
sion of PDAC cells remains unclear. We recently reported that
OBP-702-mediated p53 overexpression induces apoptosis- and auto-
phagy-related death in a variety of malignant tumor cell types.18,19
Consistent with these findings, we confirmed that OBP-702 exhibits
antitumor effects in p53 mutant PDAC cells via induction of auto-
phagy and apoptosis. Rosenfeldt et al.27 reported that autophagy sup-
presses PDAC progression in KRAS mutant and p53-deficient mice.
Figure 5. OBP-301 and OBP-702 Inhibit Tumor Growth in a Subcutaneous BxPC-3 Tumor Model
(A) BxPC-3 cells (5 106 cells/site) were inoculated into the right flanks of athymic nudemice. OBP-301 (108 PFUs), OBP-702 (108 PFUs), or PBS (mock) was injected into the
tumors on days 0, 2, and 4. Data are expressed as mean tumor volume ± SD (mock group: n = 8; OBP-301 and OBP-702 groups: n = 9). (B) Macroscopic appearance of
representative mice on day 37 after first treatment. (C) Macroscopic appearance of all isolated tumors on day 37 after first treatment. (D) Histologic analysis of BxPC-3 tumors.
Paraffin-embedded sections of BxPC-3 tumors were stained with hematoxylin and eosin (H&E) or anti-Ki-67 antibody. Left two images and right two images represent H&E
and Ki-67 staining, respectively, with low (100) and high (400) original magnification. High-magnification images are the area outlined by a black square in the low-
magnification images. (E) Percentage of Ki-67-positive cells in each group. The percentage of Ki-67-positive cells was calculated from three random fields of tumor section in
each group under microscopy. *p < 0.05.
www.moleculartherapy.orgBy contrast, Todoric et al.28 demonstrated that autophagy prevents
the development of PDAC in KRAS mutant acinar cells. Because
p53 is a strong inducer of autophagy,29,30 p53-mediated autophagy
induction could play a tumor-suppressive role in the development
and progression of p53-inactivated PDAC. Thus, OBP-702 would
have therapeutic potential for eliminating p53 mutant PDAC cells
by inducing p53-mediated autophagy.
Activation of MAPK signaling is a key factor in the development,
growth, and progression of PDAC tumors.23,24 Our data revealed
that highly invasive BxPC-3 and Panc-1 cells exhibit ERK activation,
supporting the hypothesis that ERK plays a critical role in the invasive
phenotype of PDAC cells. Previous reports demonstrated that Panc-1
cells are KRAS mutant with ERK activation,31 whereas BxPC-3 cells
are KRAS wild type.32 Recently, Chen et al.33 revealed that BxPC-3
cells have an in-frame BRAF deletion in association with ERK activa-
tion. A recent report by the Cancer Genome Atlas Research Network
also indicated the presence of an in-frame BRAF deletion in KRAS-wild-type PDAC tumors.34 Therefore, ERK activation in highly inva-
sive BxPC-3 and Panc-1 cells may be associated with KRAS and BRAF
mutations. However, poorly invasive Capan-1 and MIA PaCa-2 cells
do not exhibit ERK activation despite harboring KRAS mutations.32
Shibata et al.35 suggested that in addition to KRAS mutations, muta-
tions in p53, along with several reprogramming factors, are necessary
to activate pancreatic ERK signaling in mice. Although ERK activa-
tion plays a key role in the invasive phenotype of PDAC cells, these
cells exhibit distinct diversity in terms of their genetic background
with respect to ERK activation.
An abundance of neurosecretory factors is a common feature of the
pancreatic microenvironment,2–6 and this can contribute to local
recurrence, distant metastasis, and poor prognosis in PDAC patients.
Our data demonstrated that several neurosecretory factors (NE,
NGF, GDNF) promote the migration and invasion of highly invasive
BxPC-3 and Panc-1 cells via ERK activation. Regarding the role of
ERK activation in the invasion of BxPC-3 and Panc-1 cells, YangMolecular Therapy: Oncolytics Vol. 17 June 2020 113
Molecular Therapy: Oncolyticset al.36 recently revealed that ERK activation induces the downregula-
tion of Raf kinase inhibitory protein (RKIP), which contributes to the
invasive andmetastatic phenotype of BxPC-3 and Panc-1 cells. RKIP is
a downstream target of tumor suppressor p53, by which RKIP induc-
tion inhibits the activation of ERK signaling.37 Because p53-activating
OBP-702, but not p53-nonexpressing OBP-301, suppressed the activa-
tion of ERK in highly invasive BxPC-3 and Panc-1 cells, p53-mediated
RKIP activation may play a critical role in suppressing ERK activation
in highly invasive PDAC cells in concert with neurosecretory factors.
Subcutaneous and orthotopic xenograft tumor models using human
PDAC cell lines are frequently employed for in vivo evaluation of
therapeutic potential.38 We confirmed the in vivo antitumor effect
of OBP-301 andOBP-702 using a subcutaneous BxPC-3 xenograft tu-
mor model. Previous reports have suggested that epidermal growth
factor receptor (EGFR) plays a critical role in the development of
PDAC tumors.39,40 As we recently confirmed that OBP-301 sup-
presses EGFR expression via the accumulation of adenoviral E1A, re-
sulting in autophagy-related death of malignant tumor cells,41 the
antitumor effect of OBP-301 and OBP-702 in subcutaneous PDAC
tumors may be associated at least in part with EGFR suppression.
By contrast, experiments using an orthotopic BxPC-3 xenograft tu-
mor model demonstrated the antitumor effect of OBP-702, but not
OBP-301. Orthotopic BxPC-3 xenograft tumors have been shown
to exhibit high metastatic potential, with invasive characteristics
similar to those of clinical PDAC tumors.42 Hayes et al.43 recently re-
ported that ERK suppression reduces the growth of PDAC tumors in-
dependent of KRAS status. Because BxPC-3 cells have an in-frame
BRAF deletion in association with ERK activation,33 the OBP-702-
mediated antitumor effect against orthotopic PDAC tumors may be
associated with ERK suppression. Further experiments would be war-
ranted to explore themolecular mechanism of the OBP-702-mediated
antitumor effect against PDAC tumors.
Precision medicine therapies based on genetic alterations have
recently emerged for the treatment of various types of cancer,
including PDAC.44,45 Recent genomic sequencing studies revealed
that most PDAC cells harbor genetic alterations in four major genes:
KRAS, TP53, CDKN2A, and SMAD4.46 Yachida et al.47 suggested that
among these four driver gene mutations, a smaller number of driver
gene alterations could serve as a prognostic factor for PDAC patients
with longer survival. Hingorani et al.48 demonstrated that concomi-
tant expression of the KRASG12D and TP53R172H mutated genes
induced PDAC cell invasion and metastasis in a genetically engi-
neered mice model, suggesting that KRAS and TP53 represent potent
therapeutic targets among the four driver genes. Although KRAS pro-
tein plays a critical role in cancers involving KRAS mutations,49 ef-
forts to develop drugs targetingmutant KRAS protein in a tumor-spe-
cific manner have not been successful. Our tumor-specific oncolytic
viruses OBP-301 and OBP-702 efficiently suppressed KRAS expres-
sion in PDAC cells. In addition, recent reports demonstrated that
p53 restoration suppresses the invasion and metastasis of lung cancer
cells in KRAS and TP53 mutant mice.50,51 Indeed, p53-activating
OBP-702 suppressed the invasion of highly invasive PDAC cells114 Molecular Therapy: Oncolytics Vol. 17 June 2020more strongly than p53-nonexpressing OBP-301. Thus, OBP-702
could be a useful agent for targeting KRAS and TP53 gene alterations
in PDAC cells as a novel precision medicine tool.
In conclusion, we demonstrated that the p53-armed oncolytic adeno-
virus OBP-702 exerts an inhibitory effect on the growth and invasion
of PDAC cells via the induction of p53 expression, autophagy, and
apoptosis. OBP-702 effectively inhibited the neurosecretory factor-
enhanced migration and invasion of PDAC cells via suppression of
ERK signaling. Moreover, the OBP-702-induced antitumor activity
was effective in both subcutaneous and orthotopic PDAC xenograft
tumor models. These data suggest that OBP-702-mediated p53 reac-
tivation is a promising antitumor strategy for use against p53-inacti-
vated PDAC tumors. We have recently reported that combination
therapy with OBP-301 and chemotherapy or radiotherapy is more
effective than monotherapy of OBP-301 in various types of cancer,
such as esophageal cancer,52 gastric cancer,53 and osteosarcoma.54
Therefore, the preclinical studies to confirm the therapeutic potential
of OBP-702 are currently underway for PDAC cells in combination
with chemotherapy, radiotherapy, and immune checkpoint inhibi-
tors. Further clinical study is also warranted to confirm the safety
and feasibility of using p53-armed telomerase-specific oncolytic
adenovirus OBP-702 in patients with invasive PDAC.
MATERIALS AND METHODS
Cell Lines
The human PDAC cell lines Capan-1, MIA PaCa-2, BxPC-3, and
Panc-1 were obtained from the American Culture Type Collection.
BxPC-3 cells stably transfected with the firefly Luc expression vector
(BxPC-3-Luc) were obtained from the Japanese Collection of
Research Bioresources Cell Bank (JCRB, Osaka, Japan). Cells were
cultured for no longer than 5 months following resuscitation.
Authentication was not performed by the authors. MIA PaCa-2
and Panc-1 cells were maintained in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% fetal bovine serum (FBS). BxPC-3 and
BxPC-3-Luc cells were maintained in RPMI-1640 supplemented with
10% FBS. Capan-1 cells were maintained in Iscove’s modified Dulbec-
co’s medium supplemented with 20% FBS. All media were supple-
mented with 100 U/mL penicillin and 100 mg/mL streptomycin. Cells
were maintained at 37C in a humidified atmosphere with 5% CO2.
Recombinant Adenoviruses
The telomerase-specific replication-competent adenovirus OBP-301
(telomelysin), in which the promoter element of the hTERT gene
drives the expression of E1A and E1B genes, was constructed and
characterized previously.15–17 OBP-702 was constructed by modi-
fying OBP-301 to express the exogenous p53 gene by inserting a hu-
man wild-type p53 gene expression cassette driven by the Egr-1 pro-
moter into the E3 region of OBP-301.18 OBP-401 was constructed by
modifying OBP-301 to express the GFP by inserting a GFP gene
expression cassette into the E3 region of OBP-301.22 Recombinant
adenoviruses were purified using cesium chloride step gradients,
and virus titers were determined using a plaque-forming assay with
293 cells. Viruses were stored at 80C.
Figure 6. OBP-702 Inhibits Tumor Growth in an Orthotopic BxPC-3-Luc Xenograft Tumor Model
BxPC-3-Luc cells (3 106 cells/site) were inoculated into the pancreatic tails of athymic nude mice. OBP-301 (108 PFUs/tumor), OBP-702 (108 PFUs/tumor), or PBS (mock)
was injected into the tumors on days 0, 2, and 4. Luminescence in tumor tissues was analyzed using an IVIS system at 0, 7, 14, 21, and 28 days after first treatment. (A)
Representative photographs of mock-, OBP-301-, or OBP-702-treated tumor-bearing mice. (B) Data are expressed asmean ± SD (mock group: n = 12; OBP-301 and OBP-
702 groups: n = 10). *p < 0.05.
www.moleculartherapy.orgReagents
NE, NGF, and GDNF were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Control siRNA, KRAS siRNA, ERK1 siRNA, and ERK2
siRNA were purchased from Applied Biosystems (Foster City, CA,
USA).
Cell Viability Assay
Cells were seeded in 96-well plates at a density of 103 cells/well (MIA
PaCa-2, BxPC-3, Panc-1) or 5  103 cells/well (Capan-1) 24 h before
virus infection. Cells were infected with OBP-301, OBP-702, or OBP-
401 at a MOI of 0, 1, 5, 10, 50, or 100 plaque-forming units (PFUs)/
cell. Cell viability was determined on day 3 after virus infection using
a Cell Proliferation Kit II (Roche, Indianapolis, IN, USA) according to
the manufacturer’s protocol.
Western Blot Analysis
Cells were seeded in a 100-mm dish at a density of 105 cells/dish 24 h
before virus infection. Cells were infected with OBP-301 or OBP-702
at the indicated MOI for 72 h. Whole-cell lysates were prepared at
the indicated time points. Proteins were electrophoresed on
6%–15% SDS polyacrylamide gels and then transferred onto polyvi-
nylidene difluoride membranes (Hybond-P; GE Healthcare, Buck-
inghamshire, UK). Primary antibodies used were as follows: mouse
anti-p62monoclonal antibody (mAb) (Medical & Biological Labora-
tories, Nagoya, Japan), mouse anti-p53 mAb (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), mouse anti-Ad5 E1A mAb (BD
Pharmingen, Franklin Lakes, NJ, USA), rabbit anti-KRAS mAb
(Abcam, Cambridge, MA, USA), rabbit anti-PARP polyclonal anti-
body (pAb), rabbit anti-ERK1/2 mAb, rabbit anti-phospho-ERK1/2
mAb (Cell Signaling Technology, Danvers, MA, USA), and mouse
anti-b-actin mAb (Sigma-Aldrich). Secondary antibodies used
were as follows: horseradish peroxidase-conjugated antibodies
against rabbit IgG or mouse IgG (GE Healthcare). Immunoreactivebands on the blots were visualized using enhanced chemilumines-
cence substrates (ECL Plus; GE Healthcare).Migration and Invasion Assay
Migration assay is used to investigate themobility of tumor cells toward
a chemo-attractant through non-coated membrane. Invasion assay is
used to investigate the mobility of tumor cells with invasive capability
through extracellular matrix-coated membrane. Cell migration and in-
vasion assays were conducted using 24-well Boyden chambers equip-
ped with 8-mm pore size filter membranes and 8-mm pore size filter
membranes coated with Matrigel, respectively (BD Biosciences). For
the assays, 10% FBS-containingmediumwas placed in the lower cham-
bers to be used as a chemoattractant. To characterize PDAC cell migra-
tion and invasion, we placed 105 PDAC cells in a 500-mL volume of
serum-free medium in the upper chambers and incubated them at
37C for 24 h. Next, to assess the effect of oncolytic adenoviruses and
neurosecretory factors, we placed 5  104 cells (BxPC-3) or 2.5  104
cells (Panc-1) in the upper chambers for the migration assay, and 105
cells (BxPC-3) or 5 104 cells (Panc-1) were placed in the upper cham-
bers for the invasion assay. Twenty-four hours after treatment with on-
colytic adenoviruses and neurosecretory factors, migrating or invading
cells on the bottom surface of the membrane were stained with crystal
violet (Sigma-Aldrich) and counted under a microscope (original
magnification100) in five randomly selected fields.In Vivo Subcutaneous BxPC-3 Xenograft Tumor Model
Animal experimental protocols were approved by the Ethics Review
Committee for Animal Experimentation of Okayama University
School of Medicine (No. OKU-2015364). BxPC-3 xenograft tumors
were produced on the right flank of 6-week-old female BALB/c-nu/
nu mice (CLEA Japan, Tokyo, Japan) by subcutaneous injection of
5 106 cells in 100 mL of PBS.When tumors had grown to a diameterMolecular Therapy: Oncolytics Vol. 17 June 2020 115
Molecular Therapy: Oncolyticsof 5–7mm, OBP-301, OBP-702, or PBS was injected intratumorally at
a MOI of 108 PFUs/50 mL. Oncolytic adenovirus was injected on days
0, 2, and 4. The perpendicular diameter of each tumor was measured
every 3 or 4 days, and tumor volume was calculated using the
following formula: tumor volume (mm3) = a b2 0.5, where a rep-
resents the longest diameter, b represents the shortest diameter, and
0.5 is the constant for calculating the volume of an ellipsoid.
Histopathologic Analysis
Subcutaneous tumors were fixed in 10% neutralized formalin and
embedded in paraffin blocks. Sections were stained with hematoxylin
and eosin to assess the tumor region. Proliferating tumor cells within
tumor tissues were detected by immunostaining with rabbit anti-Ki67
mAb (Abcam) using standard techniques. Photographs of immuno-
stained sections were obtained under light microscopy. The total
number of cells and total number of Ki67-immunoreactive cells
were calculated in five randomly selected fields in each tumor using
ImageJ software.
In Vivo Orthotopic BxPC-3-Luc Xenograft Tumor Model
Animal experimental protocols were approved by the Ethics Review
Committee for Animal Experimentation of Okayama University
School of Medicine (No. OKU-2011062). BxPC-3-Luc cells sus-
pended in Matrigel at a concentration of 3  106 cells per 20 mL
were inoculated into the pancreatic tail of 6-week-old female
BALB/c-nu/nu mice during laparotomy with a small left-flank
abdominal incision. Three weeks later, mice were injected intratu-
morally with OBP-301 or OBP-702 at a MOI of 1.0  108 PFUs/
20 mL, or mice were injected with PBS during laparotomy on days
0, 7, and 14. Tumor progression was monitored by intraperitoneal
injection of the substrate luciferin (VivoGlo Luciferin; Promega,
Madison, WI, USA) at a dose of 150 mg/kg body weight. Images
were collected in the supine position every few minutes from 10 to
30 min after luciferin injection using a Xenogen IVIS Lumina
Imaging System (Caliper Life Sciences, Cheshire, UK), and photons
emitted from the abdominal region were quantified using Xenogen
Living Image Software (Caliper Life Sciences).
Statistical Analysis
Data are expressed as the mean ± SD. Significant differences were as-
sessed using the Student’s t test. Statistical significance was defined as
a p value of less than 0.05.
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